Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

See allHide authors and affiliations

Science Translational Medicine  29 May 2019:
Vol. 11, Issue 494, eaau9242
DOI: 10.1126/scitranslmed.aau9242

Nipping Nipah virus infections in the bud

Human infection with Nipah virus is often fatal, and there are no approved therapeutics. Lo et al. tested the nucleotide prodrug remdesivir (GS-5734), which has shown activity against other pathogens such as Ebola virus, in a nonhuman primate model. Animals were administered a lethal dose of Nipah virus, and half were treated daily with remdesivir starting 24 hours later. All control animals had to be euthanized, and although treated animals had some mild symptoms, all survived. These results indicate that efficacy of remdesivir should be tested in human Nipah virus infection.

View Full Text

Stay Connected to Science Translational Medicine